- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT03745066
BioFreedom French Registry
A Post-Market Registry of the BioFreedomTM Biolimus A9TM Coated Coronary Stent System
Prospective, observational multi-center registry to be conducted at up to 25 French interventional cardiology centers. Patients will be eligible once they have received at least one BioFreedomTM DCS as per standard clinical practice and will be followed for up to 2 years post PCI for data collection.
The purpose of the registry is to explore the safety and effectiveness of the BioFreedomTM DCS in standard clinical practice in France and to serve as part of Post Market Surveillance.
Studieoversikt
Status
Forhold
Detaljert beskrivelse
Prospective, observational multi-center registry to be conducted at up to 25 French interventional cardiology centers. Patients will be eligible once they have received at least one BioFreedomTM DCS as per standard clinical practice and will be followed for up to 2 years post PCI for data collection.
The registry will be purely observational and will not interfere with physician's decisions relating to stent selection or indication for treatment.
The purpose of the registry is to explore the safety and effectiveness of the BioFreedomTM DCS in standard clinical practice in France and to serve as part of Post Market Surveillance.
Studietype
Registrering (Forventet)
Kontakter og plasseringer
Studiesteder
-
-
-
Fontaine-lès-Dijon, Frankrike, 21121
- Clinique de Fontaine
-
Haguenau Cedex, Frankrike, 67504
- Centre Hospitalier General
-
Pessac, Frankrike, 33600
- Clinique Saint Martin
-
Toulouse, Frankrike
- CHU Toulouse Rangeuil
-
-
Cedex 2
-
Clermont-ferrand, Cedex 2, Frankrike, 63050
- Clinique Des Dômes
-
-
Essonne
-
Quincy sous Sénart, Essonne, Frankrike, 91480
- at Hôpital Privé Claude Galien ICPS
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Barn
- Voksen
- Eldre voksen
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Beskrivelse
Inclusion Criteria:
- Patients treated with one or more BioFreedom™ DCS .Patients who agree to comply with the follow up requirements. .Patients with a life expectancy of > 1 year at time of consent. .Patients eligible to receive dual anti platelet therapy (DAPT).
- Patients who have signed an Informed Consent
Exclusion Criteria:
- Patients unable or unwilling to give documented informed consent
- Patients taking part in another interventional trial which has not completed follow-up for the primary endpoint .Patient has received an additional stent different from a BioFreedom™ DCS stent during the index procedure.
- Pregnant or breastfeeding women
- Planned surgery within 6 months of percutaneous coronary intervention (PCI) unless dual antiplatelet therapy is maintained throughout the peri surgical period for non HBR patients
- Planned surgery within 1 month of percutaneous coronary intervention (PCI) unless dual antiplatelet therapy is maintained throughout the peri surgical period for HBR patients
- Patients under judicial protection, tutorship or curatorship
Studieplan
Hvordan er studiet utformet?
Designdetaljer
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
DOCE
Tidsramme: 1 year
|
Device-oriented composite endpoint (DOCE) at 12 months defined as composite of cardiovascular death (CD), myocardial infarction (MI) not clearly attributable to a non-target vessel and clinically driven target lesion revascularization (cd-TLR).
|
1 year
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
All-cause mortality
Tidsramme: 12-month and 24-month
|
1. All-cause mortality, CD, non-cardiovascular and undetermined death in hospital and at 12 and 24 months
|
12-month and 24-month
|
Patient-oriented composite endpoint (POCE) at 12 and 24 months
Tidsramme: 12 months and 2 years
|
Patient-oriented composite endpoint (POCE) at 12 and 24 months defined as all-cause mortality, any stroke, any MI (including nontarget vessel territory) and any revascularization.
|
12 months and 2 years
|
Composite of Cardiovascular Death (CD) at 12 and 24 months
Tidsramme: 12 months and 2 years
|
Composite of CD, MI and definite/probable stent thrombosis (ST) at 12 and 24 months.
|
12 months and 2 years
|
Definite/probable ST at 12 and 24 months
Tidsramme: 12 months and 24 months
|
Definite/probable ST at 12 and 24 months
|
12 months and 24 months
|
Target Vessel Failure defined at 12 and 24 months
Tidsramme: 12 months and 24 months
|
Target Vessel Failure (TVF) defined as CD, target-vessel-related MI, and Target vessel revascularization (TVR) at 12 and 24 months
|
12 months and 24 months
|
Target Lesion Failure at 12 and 24 months
Tidsramme: 12 months and 24 months
|
Target Lesion Failure (TLF) defined as CD, target-vessel-related MI, and clinically driven TLR at 12 and 24 months
|
12 months and 24 months
|
Clinically driven TLR at any follow-up time point
Tidsramme: Inclusion, 12 months and 24 months
|
Clinically driven TLR at any follow-up time point
|
Inclusion, 12 months and 24 months
|
Clinically driven TVR at any follow-up time point
Tidsramme: Inclusion, 12 months and 24 months
|
Clinically driven TVR at any follow-up time point
|
Inclusion, 12 months and 24 months
|
Any revascularization
Tidsramme: within 24 months following the index procedure
|
Any revascularization within 24 months following the index procedure, unless they are planned within the 1st month
|
within 24 months following the index procedure
|
Stroke, disabling and non-disabling.
Tidsramme: Inclusion, 12 months and 24 months
|
Stroke, disabling and non-disabling.
|
Inclusion, 12 months and 24 months
|
BARC 3 to 5 bleeding
Tidsramme: Inclusion, 12 months and 24 months
|
BARC 3 to 5 bleeding
|
Inclusion, 12 months and 24 months
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Janusz Lipiecki, MD, Clinique Des Dômes
- Hovedetterforsker: Philippe Garot, MD, ICPS, Massy
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Forventet)
Studiet fullført (Forventet)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 18-EU-01
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Koronararteriesykdom
-
IRCCS Policlinico S. DonatoRekrutteringAnomalous aortic origin of the coronary artery (AAOCA)Italia
-
Medtronic CardiovascularFullførtArteriosclerosis of coronary artery bypass graftCanada, Forente stater
-
Lawson Health Research InstituteFullførtArteriosclerosis of arterial coronary artery bypass graftCanada
-
Deutsches Herzzentrum MuenchenFullførtArteriosclerosis of arterial coronary artery bypass graftTyskland
-
William Beaumont HospitalsFullførtKoronararteriesykdom | Arteriosclerosis of coronary artery bypass graftForente stater
-
Izmir Bakircay UniversityFullførtMyocardial Bridge of Coronary ArteryTyrkia
-
ITAB - Institute for Advanced Biomedical TechnologiesAzienda Ospedaliero, Universitaria Ospedali RiunitiFullførtMyocardial Bridge of Coronary ArteryItalia
-
University Hospital OstravaRekrutteringIn-Stent Carotis Artery RestenosisTsjekkia
-
Sohag UniversityHar ikke rekruttert ennåUmblical artery Doppler under termin graviditetEgypt
-
Baylor College of MedicineFullførtLungeblødning | MAPCA - Major Aortopulmonary Collateral ArteryForente stater